Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1923]
News [3529]
Articles [90]
Editorials [5]
Conferences [156]
elearning [19]
Association between tTMB and clinical outcomes with pembrolizumab alone in PD...
Prof Roy Herbst - Yale Cancer Center, New Haven, USA
Association between tTMB and clinical outcomes with pembrolizumab alone in PD-L1-positive advanced NSCLC in KEYNOTE-010 and -042 ( Prof Roy Herbst - Yale Cancer Center, New Haven, USA )
4 Oct 2019
IMPALA results: Lefitolimod vs standard of care in metastatic colorectal cancer
Dr Ramon Salazar - Catalan Institute of Oncology, Barcelona, Spain
IMPALA results: Lefitolimod vs standard of care in metastatic colorectal cancer ( Dr Ramon Salazar - Catalan Institute of Oncology, Barcelona, Spain )
4 Oct 2019
MEDIOLA: Olaparib and durvalumab for germline BRCA-mutated metastatic breast...
Prof Susan Domchek - University of Pennsylvania, Pennsylvania, USA
MEDIOLA: Olaparib and durvalumab for germline BRCA-mutated metastatic breast cancer ( Prof Susan Domchek - University of Pennsylvania, Pennsylvania, USA )
4 Oct 2019
Blood first assay screening in patients with ALK positive NSCLC
Prof Shirish Gadgeel - University of Michigan, Ann Arbor, USA
Blood first assay screening in patients with ALK positive NSCLC ( Prof Shirish Gadgeel - University of Michigan, Ann Arbor, USA )
4 Oct 2019
CUPISCO: Identifying carcinoma of unknown primary patients according to ESMO...
Prof Jeffrey S. Ross - Albany Medical Center, Albany, USA
CUPISCO: Identifying carcinoma of unknown primary patients according to ESMO guidelines ( Prof Jeffrey S. Ross - Albany Medical Center, Albany, USA )
4 Oct 2019
CheckMate 459: Safety and efficacy of nivolumab versus sorafenib as a first...
Dr Thomas Yau - The University of Hong Kong, Hong Kong
CheckMate 459: Safety and efficacy of nivolumab versus sorafenib as a first-line treatment in advanced hepatocellular carcinoma ( Dr Thomas Yau - The University of Hong Kong, Hong Kong )
4 Oct 2019
Precision medicine in ALK-positive NSCLC: Results from the BFAST trial
Prof Solange Peters and Prof Tony Mok
Precision medicine in ALK-positive NSCLC: Results from the BFAST trial ( Prof Solange Peters and Prof Tony Mok )
3 Oct 2019
Breast cancer highlights from ESMO 2019
Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy
Breast cancer highlights from ESMO 2019 ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )
2 Oct 2019
Melanoma highlights from ESMO 2019
Dr Teresa Amaral - University Hospital Tübingen, Tübingen, Germany
Melanoma highlights from ESMO 2019 ( Dr Teresa Amaral - University Hospital Tübingen, Tübingen, Germany )
30 Sep 2019
IMvigor130: Immunotherapy added to chemotherapy in metastatic urothelial cancer
Dr Enrique Grande - Hospital MD Anderson Cancer Center Madrid, Madrid, Spain
IMvigor130: Immunotherapy added to chemotherapy in metastatic urothelial cancer ( Dr Enrique Grande - Hospital MD Anderson Cancer Center Madrid, Madrid, Spain )
30 Sep 2019
Bladder cancer: Latest advances in targeted therapies and precision medicine...
Dr Javier Puente, Prof Maria De Santis, Dr Yohann Loriot, Dr Eva Comperat and...
Bladder cancer: Latest advances in targeted therapies and precision medicine from ESMO 2019 ( Dr Javier Puente, Prof Maria De Santis, Dr Yohann Loriot, Dr Eva Comperat and Dr Michiel Van der Heijden )
30 Sep 2019
Latest developments in metastatic prostate cancer from ESMO 2019
Prof Nick James and Prof Nicholas Mottet
Latest developments in metastatic prostate cancer from ESMO 2019 ( Prof Nick James and Prof Nicholas Mottet )
30 Sep 2019

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation